ANNX Annexin Pharmaceuticals AB
Debt Financing ·
Annexon drew $50 million at closing on a credit facility of up to $200 million from Oxford Finance LLC. Another $100 million depends on registrational milestones, and $50 million needs lender approval.
Annexon's stockholders approved raising authorized common stock from 300,000,000 to 500,000,000 shares on June 11, 2026, with 8,795,454 abstentions and no reason given for the increase.
Annexon priced 25,096,153 shares at $2.60 for about $75 million on November 12, 2025, with pre-funded warrants for up to 3,750,000 more shares, and its two lead programs are still in late-stage trials.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $184.7 million | $119.4 million |
| Net income (loss) | -$206.7 million | -$138.2 million |
| Cash from operations | -$186.4 million | -$118.0 million |
| Cash and equivalents | $162.1 million | $49.5 million |
| Short-term investments | $76.3 million | $262.5 million |
Our latest story on this, dated Nov 12, 2025: "Annexon proposes $75,000,000 stock offering, prices shares at $2.60". The story links the filing or release it is based on. Read the story.
Annexin Pharmaceuticals AB trades under the ticker ANNX on OMXSTO.
Annexin Pharmaceuticals AB is listed on OMXSTO.
Our directory records Annexin Pharmaceuticals AB under Sweden.
Our directory classifies Annexin Pharmaceuticals AB as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Annexin Pharmaceuticals AB is SE0025159387.
aibio.space lists Annexin Pharmaceuticals AB among 2,820 public biotech companies and publishes its news here as stories appear.
Annexin Pharmaceuticals AB reported a net loss of $206.7 million for the fiscal year ended Dec 31, 2025, and used $186.4 million of cash in operations, per its annual report to the SEC.
$184.7 million in the fiscal year ended Dec 31, 2025, per its annual report.
$209.2 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Our latest story on Annexin Pharmaceuticals AB, dated Jul 30, 2026: "Annexon secures credit facility of up to $200 million from Oxford Finance". Annexon drew $50 million at closing on a credit facility of up to $200 million from Oxford Finance LLC. Another $100 million depends on registrational milestones, and $50 million needs lender approval. Source.
Our latest debt story, dated Jul 30, 2026: "Annexon secures credit facility of up to $200 million from Oxford Finance". Annexon drew $50 million at closing on a credit facility of up to $200 million from Oxford Finance LLC. Another $100 million depends on registrational milestones, and $50 million needs lender approval. Source.
Our latest listing story, dated Jun 12, 2026: "Annexon holders approve raising authorized common shares to 500,000,000". Annexon's stockholders approved raising authorized common stock from 300,000,000 to 500,000,000 shares on June 11, 2026, with 8,795,454 abstentions and no reason given for the increase. Source.
Companies in our directory listed in the same country and business area as Annexin Pharmaceuticals AB: Alzinova AB, Infant Bacterial Therapeutics AB, Diamyd Medical AB, Sprint Bioscience AB, Coegin Pharma AB, Newbury Pharmaceuticals AB.
Press Follow on this page to add Annexin Pharmaceuticals AB to your Following list, or subscribe to the aibio.space newsletter. We have published 3 stories naming Annexin Pharmaceuticals AB so far, in Debt Financing, Financings, Listings.
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio